243 related articles for article (PubMed ID: 9552036)
21. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
J Clin Oncol; 1993 Mar; 11(3):467-73. PubMed ID: 8445422
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancer.
Hebbar M; Bonneterre J; Fournier C; Vanlemmens L; Pion JM; Adenis A; Kamus E; Hecquet B; Conroy T; Tubiana-Hulin M
J Infus Chemother; 1995; 5(4):201-5. PubMed ID: 8934728
[TBL] [Abstract][Full Text] [Related]
23. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
J Clin Oncol; 1991 Feb; 9(2):305-12. PubMed ID: 1988577
[TBL] [Abstract][Full Text] [Related]
24. Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.
Klaassen U; Wilke H; Müller C; Borquez D; Korn M; Achterrath W; Harstrick A; Diergarten K; Seeber S
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):38-40. PubMed ID: 9144690
[TBL] [Abstract][Full Text] [Related]
25. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
Klaassen U; Wilke H; Müller C; Borquez D; Harstrick A; Seeber S
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095
[TBL] [Abstract][Full Text] [Related]
26. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial.
Focan C; Andrien JM; Closon MT; Dicato M; Driesschaert P; Focan-Henrard D; Lemaire M; Lobelle JP; Longree L; Ries F
J Clin Oncol; 1993 Jul; 11(7):1253-63. PubMed ID: 8315422
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
Joensuu H; Holli K; Heikkinen M; Suonio E; Aro AR; Hietanen P; Huovinen R
J Clin Oncol; 1998 Dec; 16(12):3720-30. PubMed ID: 9850014
[TBL] [Abstract][Full Text] [Related]
28. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
Capotorto AM; Pavesi L; Pedrazzoli P; Da Prada GA; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
J Chemother; 2003 Apr; 15(2):184-91. PubMed ID: 12797397
[TBL] [Abstract][Full Text] [Related]
29. Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Cancello G; Bagnardi V; Sangalli C; Montagna E; Dellapasqua S; Sporchia A; Iorfida M; Viale G; Barberis M; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2015 Aug; 15(4):259-65. PubMed ID: 25933934
[TBL] [Abstract][Full Text] [Related]
30. Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen.
Hügli A; Sappino AP; Anchisi S; Mermillod B; Schafer P; Anguenot JL; Bonnefoi H
Ann Oncol; 2000 Dec; 11(12):1557-61. PubMed ID: 11205463
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma.
Periti P; Pannuti F; Della Cuna GR; Mazzei T; Mini E; Martoni A; Preti P; Ercolino L; Pavesi L; Ribecco A
Cancer Invest; 1991; 9(3):249-55. PubMed ID: 1913227
[TBL] [Abstract][Full Text] [Related]
32. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.
Smith IE; Walsh G; Jones A; Prendiville J; Johnston S; Gusterson B; Ramage F; Robertshaw H; Sacks N; Ebbs S
J Clin Oncol; 1995 Feb; 13(2):424-9. PubMed ID: 7844604
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
Evans TR; Lofts FJ; Mansi JL; Glees JP; Dalgleish AG; Knight MJ
Br J Cancer; 1996 May; 73(10):1260-4. PubMed ID: 8630289
[TBL] [Abstract][Full Text] [Related]
34. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A
Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307
[TBL] [Abstract][Full Text] [Related]
36. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.
French Epirubicin Study Group
J Clin Oncol; 2000 Sep; 18(17):3115-24. PubMed ID: 10963640
[TBL] [Abstract][Full Text] [Related]
37. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
Içli F; Celik I; Aykan F; Uner A; Demirkazik A; Ozet A; Ozgüroğlu M; Taş F; Akbulut H; Firat D
Cancer; 1998 Dec; 83(12):2475-80. PubMed ID: 9874451
[TBL] [Abstract][Full Text] [Related]
38. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
39. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
Del Mastro L; Levaggi A; Michelotti A; Cavazzini G; Adami F; Scotto T; Piras M; Danese S; Garrone O; Durando A; Accortanzo V; Bighin C; Miglietta L; Pastorino S; Pronzato P; Castiglione F; Landucci E; Conte P; Bruzzi P
Breast Cancer Res Treat; 2016 Jan; 155(1):117-26. PubMed ID: 26661403
[TBL] [Abstract][Full Text] [Related]
40. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Langley RE; Carmichael J; Jones AL; Cameron DA; Qian W; Uscinska B; Howell A; Parmar M
J Clin Oncol; 2005 Nov; 23(33):8322-30. PubMed ID: 16293863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
